DelveInsight’s “Postoperative Pain Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Postoperative Pain, historical and forecasted epidemiology as well as the Postoperative Pain market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Postoperative Pain market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Postoperative Pain Market Forecast

Some of the key facts of the Postoperative Pain Market Report:

• The Postoperative Pain market size was valued ~USD 2,979 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)

• In February 2025, Allay Therapeutics administered the first dose in its randomized Phase IIb registration trial evaluating ATX101, an investigational analgesic aimed at delivering prolonged pain relief after total knee replacement surgery.

• In November 2024, PainReform is a clinical-stage specialty pharma company dedicated to improving existing therapies through reformulation. Its lead candidate, PRF-110, is a novel formulation of the local anesthetic ropivacaine, developed for managing postoperative pain. PRF-110 is a clear, oil-based, viscous solution administered directly into the surgical wound site before closure, delivering targeted and prolonged pain relief following surgery.

• In January 2024, Heron Therapeutics announced that the FDA approved its supplemental New Drug Application (sNDA) for bupivacaine and meloxicam extended-release solution. The approval expands its indication to include soft tissue and orthopedic surgical procedures, specifically those where direct exposure to articular cartilage is avoided.

• The postoperative pain market size in the United States was approximately USD 2,606 million in 2023 and is expected to grow, driven by rising awareness of the condition and the introduction of emerging therapies.

• In 2023, the postoperative pain market size in EU4 and the UK was estimated at approximately USD 232 million, accounting for around 8% of the total market revenue in the 7MM.

• Several leading postoperative pain companies are advancing their key drug candidates through various stages of clinical development, including IV Tramadol by Avenue Therapeutics, Opiranserin (VVZ-149) Injections by Vivozon, OCS-01 by Oculis, among others.

• In 2023, the 7MM recorded approximately 67 million incident cases of postoperative pain. This number is projected to rise by 2034, driven by an increase in traffic accidents, trauma-related injuries, and the growing demand for pain management after surgeries.

• In 2023, the US accounted for the highest proportion of incident postoperative pain cases, contributing approximately 60.41% of the total cases in the 7MM. Meanwhile, EU4 and the UK represented around 21.14%, while Japan accounted for approximately 18.43% of the total cases.

• As per DelveInsight, in 2023, the estimated severity-specific incident cases of postoperative pain in France were approximately 1.2 million mild cases, 1.5 million moderate cases, and 0.8 million severe cases. These numbers are projected to rise by 2034 due to an increasing incidence of postoperative pain.

• In 2023, the estimated severity-specific incident cases of postoperative pain in Germany were approximately 1.4 million mild cases, 1.7 million moderate cases, and 1 million severe cases. These figures are projected to rise throughout the forecast period (2024–2034).

• In the UK, around 4,050,000 new cases of postoperative pain were reported in 2023.

• Key Postoperative Pain Companies: Ocular Therapeutix, Heron Therapeutics, Avenue Therapeutics, Taiwan Liposome Company (TLC), Teikoku Pharma USA, Concentric Analgesics, Salvat Laboratories, Vertex Pharmaceuticals, Oculis, Baudax Bio, Jiangsu HengRui Medicine, Darnitsa Pharma, Adynxx, Inc., Pacira Pharma, Apsen Farmaceutica S.A., Durect, Pfizer, Vivozon, Inc., Grünenthal GmbH, Mallinckrodt, Astellas Pharma Inc, Ferndale Laboratories, Inc., and others

• Key Postoperative Pain Therapies: DEXTENZA (dexamethasone), ZYNRELEF (bupivacaine and meloxicam), IV Tramadol, TLC590, TPU-006, CA-008, SVT-15473, VX-548, OCS-01, N1539, SHR0410, Ketorolac tromethamine, AYX1, EXPAREL, Toragesic®, SABER-Bupivacaine, lyrica, VVZ-149, Tapentadol (OS), Percocet, YM177, LMX4, and others

• The Postoperative Pain market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Postoperative Pain pipeline products will significantly revolutionize the Postoperative Pain market dynamics.

Postoperative Pain Overview

Postoperative pain refers to pain that occurs after surgery. It is a common outcome following surgical procedures and can vary widely in intensity and duration depending on factors such as the type of surgery, individual pain tolerance, and the effectiveness of pain management strategies employed by healthcare providers.

Get a Free sample for the Postoperative Pain Market Report:

https://www.delveinsight.com/report-store/postoperative-pain-market

Postoperative Pain Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Postoperative Pain Epidemiology Segmentation:

The Postoperative Pain market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Number of Incident Cases of Postoperative Pain in the 7MM

• Total Number of Surgical Procedures(inpatient and outpatient) in the 7MM

• Severity-specific Incident Cases of Postoperative Pain in the 7MM

Download the report to understand which factors are driving Postoperative Pain epidemiology trends @ Postoperative Pain Epidemiology Forecast

Postoperative Pain Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Postoperative Pain market or expected to get launched during the study period. The analysis covers Postoperative Pain market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Postoperative Pain Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Postoperative Pain Therapies and Key Companies

• DEXTENZA (dexamethasone): Ocular Therapeutix

• ZYNRELEF (bupivacaine and meloxicam): Heron Therapeutics

• IV Tramadol: Avenue Therapeutics

• TLC590: Taiwan Liposome Company (TLC)

• TPU-006: Teikoku Pharma USA

• CA-008: Concentric Analgesics

• SVT-15473: Salvat Laboratories

• VX-548: Vertex Pharmaceuticals

• OCS-01: Oculis

• N1539: Baudax Bio

• SHR0410: Jiangsu HengRui Medicine

• Ketorolac tromethamine: Darnitsa Pharma

• AYX1: Adynxx, Inc.

• EXPAREL: Pacira Pharma

• Toragesic®: Apsen Farmaceutica S.A.

• SABER-Bupivacaine: Durect

• lyrica: Pfizer

• VVZ-149: Vivozon, Inc.

• Tapentadol (OS): Grünenthal GmbH

• Percocet: Mallinckrodt

• YM177: Astellas Pharma Inc

• LMX4: Ferndale Laboratories, Inc.

Discover more about therapies set to grab major Postoperative Pain market share @ Postoperative Pain Treatment Market

Postoperative Pain Market Strengths

• Drugs with a novel mechanism of action would provide new treatment options to the patients. For instance, SVT-15473 is a “superpotent” corticosteroid that has never been used before as eye drops.

• Upcoming therapies are majorly non-opioids which are as effective, and this would reduce opioid dependence and other safety concerns associated with the current opioid medications.

Postoperative Pain Market Opportunities

• Increased public awareness creates a lucrative opportunity for the innovation of therapeutics to drive this market.

• Multimodal treatments can be prescribed to reduce the dependency on single-modal treatment. Launching such products will increase the potential ability to treat postoperative pain.

Scope of the Postoperative Pain Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Postoperative Pain Companies: Ocular Therapeutix, Heron Therapeutics, Avenue Therapeutics, Taiwan Liposome Company (TLC), Teikoku Pharma USA, Concentric Analgesics, Salvat Laboratories, Vertex Pharmaceuticals, Oculis, Baudax Bio, Jiangsu HengRui Medicine, Darnitsa Pharma, Adynxx, Inc., Pacira Pharma, Apsen Farmaceutica S.A., Durect, Pfizer, Vivozon, Inc., Grünenthal GmbH, Mallinckrodt, Astellas Pharma Inc, Ferndale Laboratories, Inc., and others

• Key Postoperative Pain Therapies: DEXTENZA (dexamethasone), ZYNRELEF (bupivacaine and meloxicam), IV Tramadol, TLC590, TPU-006, CA-008, SVT-15473, VX-548, OCS-01, N1539, SHR0410, Ketorolac tromethamine, AYX1, EXPAREL, Toragesic®, SABER-Bupivacaine, lyrica, VVZ-149, Tapentadol (OS), Percocet, YM177, LMX4, and others

• Postoperative Pain Therapeutic Assessment: Postoperative Pain current marketed and Postoperative Pain emerging therapies

• Postoperative Pain Market Dynamics: Postoperative Pain market drivers and Postoperative Pain market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Postoperative Pain Unmet Needs, KOL’s views, Analyst’s views, Postoperative Pain Market Access and Reimbursement

To know more about Postoperative Pain companies working in the treatment market, visit @ Postoperative Pain Clinical Trials and Therapeutic Assessment

Table of Contents

1. Postoperative Pain Market Report Introduction

2. Executive Summary for Postoperative Pain

3. SWOT analysis of Postoperative Pain

4. Postoperative Pain Patient Share (%) Overview at a Glance

5. Postoperative Pain Market Overview at a Glance

6. Postoperative Pain Disease Background and Overview

7. Postoperative Pain Epidemiology and Patient Population

8. Country-Specific Patient Population of Postoperative Pain

9. Postoperative Pain Current Treatment and Medical Practices

10. Postoperative Pain Unmet Needs

11. Postoperative Pain Emerging Therapies

12. Postoperative Pain Market Outlook

13. Country-Wise Postoperative Pain Market Analysis (2020–2034)

14. Postoperative Pain Market Access and Reimbursement of Therapies

15. Postoperative Pain Market Drivers

16. Postoperative Pain Market Barriers

17. Postoperative Pain Appendix

18. Postoperative Pain Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/